Splink

Splink operates in healthcare, with a particular focus on brain health and neurological care. Its stated approach combines brain science and AI to support prevention, early detection, diagnosis, and management of conditions such as dementia. The product portfolio spans MRI analysis—Brain Life Imaging® and Braineer—and short cognitive self-assessments through CQ test® and mCQ®. Brain Life Imaging® + is described as combining brain imaging with cognitive screening. This gives Splink offerings across both clinical imaging assessment and accessible cognitive checks, rather than a single standalone diagnostic tool. The company is privately held and its last disclosed financing was a Seed round in November 2021; its employee-size band is 11–50. Its observable differentiation is its combination of MRI-derived brain measures and brief memory-and-attention screening within a brain-health-focused product set. The 2026 JETRO program selection provides a recent medical-data milestone, but does not by itself establish market share or commercial scale.

Splink was founded in 2017 and has developed a portfolio of five products focused on brain-health assessment. The products cover MRI-based measurement of hippocampal volume and brain atrophy, as well as cognitive self-checks designed to take about three minutes. Brain Life Imaging® + combines imaging and cognitive screening, indicating a product offering that brings two assessment modes together. A significant financing milestone came on Nov 17, 2021, when Splink announced a ¥1.12 billion Seed round, approximately $9.81 million, with four participating investors: Hakuhodo DY Holdings, Mitsubishi UFJ Capital, JAFCO, and Tokio Marine & Nichido Fire Insurance. More recently, on Aug 17, 2026, Splink was selected for JETRO’s J-StarX Medical Data Utilization Program.